JBIOJade Biosciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+19% of shares).
Rangebound, no clear trend. Oversold (RSI 27). Price is −19% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How JBIO is trading
Jade Biosciences, Inc. is +94% over the past year while the S&P 500 is +18%: 76 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 27
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 46%
Below its 52-week high
Details›
- Last close2026-10-09
- $14.42
- 1 monthS&P 500 +2.7%
- −25%
- 1 yearS&P 500 +18%
- +94%
- 5 yearsS&P 500 +88%
- −98%
- vs 50-day average$18.85
- −23%
- 52-week high
- $26.85
- 52-week low
- $7.61
- Annualised volatility
- 95%
| Year | Return |
|---|---|
| 2026 (year to date) | −6.5% |
| 2025 | −83% |
| 2024 | −88% |
| 2023 | −23% |
| 2022 | +149% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 2 of 5 | −7.3% |
| Feb | 5 | 2 of 5 | −0.49% |
| Mar | 5 | 3 of 5 | +19% |
| Apr | 5 | 2 of 5 | −15% |
| May | 5 | 0 of 5 | −15% |
| Jun | 5 | 4 of 5 | −3.0% |
| Jul | 6 | 3 of 6 | −4.6% |
| Aug | 6 | 4 of 6 | +6.2% |
| Sep | 6 | 3 of 6 | −4.2% |
| Oct | 6 | 4 of 6 | +0.88% |
| Nov | 5 | 3 of 5 | +14% |
| Dec | 5 | 4 of 5 | +21% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.